Friday 29th of March 2024
|
|
|
Headlines : * 16 new Covid cases reported in country   * Japan to provide 2,294 m Japanese Yen to Bangladesh; deals signed   * BNP wants to nullify meaning of independence: Obaidul Quader   * Rain with temporary gusty wind likely over Country   * 3 die as bus hits auto-rickshaw in M`sing   * 15 ferries, 20 launches to ply on Daulatdia-Paturia route during Eid   * Six houses gutted in Rangamati fire   * Baltimore divers recover 2 bodies from harbor after bridge collapse   * Bangladeshi youth shot dead by police in US   * Govt to import 50,000 metric tons of onion from India  

   Health
In reversal, the FDA delays push for shots for children younger than 5
  Date : 29-03-2024

Fiona Backes, 5, sits with her mother after her first dose of the Pfizer-BioNTech coronavirus vaccine, at a high school gym in Southfield, Mich, Nov 9, 2021. In a striking reversal, federal regulators said on Feb 11, 2022 that they would wait for data on whether three doses of Pfizer-BioNTech’s vaccine are effective in children younger than 5 before deciding whether to authorise a vaccine for the age group. Emily Elconin/The New York Times

In a striking reversal, federal regulators Friday said they would wait for data on how well three doses of Pfizer-BioNTech’s coronavirus vaccine work in children younger than 5 before deciding whether to authorise the vaccine for that age group.

The decision by the Food and Drug Administration most likely rules out shots for roughly 18 million of the nation’s youngest children until at least April. The Biden administration had been hoping to expand vaccination to those 6 months through 4 years of age as early as next week. They are the only Americans not yet eligible for shots.

Pfizer-BioNTech asked for the delay after the companies discovered that the omicron wave had led to a far higher rate of infection than they had previously recorded among young volunteers in their clinical trial. The new data underscored that the omicron variant was better than the earlier delta variant at evading the vaccine’s protection, and it showed that two doses, which had already fallen short by another measure, were not effective enough.

As a result, the companies and the FDA agreed to wait for the results from a third dose, which are expected in early April.

The turnabout came as the Centers for Disease Control and Prevention on Friday released data showing that booster shots of the Pfizer and Moderna vaccines lose some of their effectiveness against emergency room visits and hospitalisations by the four-month point. The agency said the data was some of earliest evidence on the durability of boosters. Although it showed three doses offered better protection than two, it raised sobering questions about how long that protection lasts against severe disease.

Together, the two developments dampened some earlier optimism about vaccines. They also presented at least a temporary setback for the Biden administration’s vaccination campaign.

Researchers hope that by April, Pfizer and BioNTech will be able to demonstrate that three doses protect children, with data showing both stronger immune responses and more success in warding off symptomatic infections.

The companies said in a news release that they would wait for the data on a three-dose vaccine given the study’s rapid pace and because they “continue to believe it may provide a higher level of protection in this age group.”

The FDA began pressing Pfizer-BioNTech to seek authorisation for a two-shot regimen weeks ago, despite disappointing results from the trial that were announced in December. Children ages 2-4 produced only 60% of the antibody levels that older teens and young adults did. The older age group was used as a bench mark because the vaccine had proved effective for them.

Children ages 6 months to 2 years did produce the sought-after level of antibodies. The dosage was one-tenth of that given to those 12 and older, and there were no serious safety concerns, officials have said.

This month, Pfizer-BioNTech submitted a request for emergency authorisation, and the FDA scheduled a meeting of its outside advisory committee for Tuesday, saying it hoped to get a head start on vaccinating young children with two shots, probably adding a third later.

Then, late Thursday, Pfizer alerted the FDA that it had more recent data, from mid-January on, showing a more discouraging picture as the omicron variant bore down. The new data revealed that two doses were not sufficiently effective in preventing symptomatic infection. The illness was generally mild and no children were hospitalised, according to people familiar with the study.

In a call with reporters Friday, Dr Peter Marks, the FDA’s top vaccine regulator and an advocate of the two-dose strategy, said the latest data had forced a new reckoning. “Yes, some of this was late breaking,” he said, “but that’s what our job is — to adjust to it.”


Although many paediatric experts had been sympathetic to the FDA’s initial push to consider two doses, some on Friday said the regulators were right to hold off.

“I honestly let out a woo-hoo of elation that reason and science had prevailed, and that they actually really did do the right thing,” said Dr. James Conway, a paediatric infectious disease expert at the University of Wisconsin-Madison and a fellow of the American Academy of Paediatrics.

Conway said he had been concerned that prematurely authorising a partial vaccine regimen for young children without compelling data would have intensified suspicion among some Americans that the federal government had cut corners.

Norman Baylor, a former director of the FDA’s vaccines office, said the agency had been “reactionary” on a highly delicate issue, perhaps because of public pressure. A lot of parents, he noted, had been saying, “I don’t care, just give my kid the two doses, and even if it’s a little bit and they’re not protected fully, that’ll do the trick.”

“But we don’t know that until the data are reviewed,” he said.

Baylor and some other experts questioned whether any coronavirus vaccine developer had yet figured out an effective dose for the youngest children, or how durable protection would be for them. Moderna, the other major vaccine manufacturer, is currently testing a stronger dose than Pfizer’s for children younger than 5. But so far, Moderna’s vaccine has only been authorised for adults.

Some parents on Friday expressed anguish over the news.

“I’m feeling despair, despondent, frustrated, confused,” said Rachel Perera, a graduate student in Los Angeles and mother of an 8-month-old son. “I feel like the goal posts have been moving.”

Perera said she had been hoping to make a long-awaited trip to the East Coast this spring to see friends and introduce them to her son. She and her husband have been avoiding most contact with others during the omicron wave in order to protect him.

“I was hoping that we would have some hope, that it would help us get some semblance of normalcy,” she said of the vaccine for children younger than 5. “I feel like the world is moving on without us, the parents of little kids.”

The FDA’s most recent vaccine decisions have been highly fraught. Top Biden administration health officials pushed hard for authorisation of booster shots in the fall, only to be forced to scale back their plans. But they were vindicated, some experts say, when the omicron variant showed that it could more easily evade two-dose protection than its predecessor, the delta variant.

At least several members of the FDA’s outside advisory panel were sceptical of the two-dose plan for the children younger than 5, and it was not clear that the panel would have recommended it.

The panel’s advice is not binding, but the FDA usually follows it.

 

The meeting scheduled for Tuesday had been expected to focus on just how urgent a priority the FDA and its outside advisers consider vaccination to be for the youngest age group. Dr Ofer Levy, a paediatrician at Harvard Medical School and member of the FDA advisory committee, on Friday said the agency would have been criticised no matter how it ruled.

“They’re under intense pressure,” he said. “I don’t envy them.”

Some infectious-disease experts have argued there was not enough of an emergency to justify the FDA’s push to authorise two doses, given the combination of the trial results, the decline in omicron cases in many parts of the country and the fact that young children are unlikely to become severely ill from the virus.

Others argued that the toll of the virus on children required the FDA to jump-start its review process. Nearly 400 children younger than 5 have died of COVID-19 since the beginning of the pandemic. Even if omicron is fading, those experts argued, another variant could emerge as a new threat just as unexpectedly as omicron did in November.

Children have been more at risk during the omicron wave, paediatricians have said.

Dr Kristin Moffitt, a physician at Boston Children’s Hospital, said that as more young children showed up in hospitals this winter, many of those she saw in her hospital were more prone to severe illness because they had existing health conditions, including congenital heart disease or immune deficiencies.

“Those with underlying conditions tended to be more severe and require ICU care,” she said. “The majority needed a couple of days of oxygen supplementation, as well as help staying hydrated.”

Dr Jessica Snowden, chief of the paediatric infectious disease division at Arkansas Children’s Hospital, said COVID-19 cases at her hospital had fallen from a daily peak of 46 in mid-January to 19.

Still, she said, “I hear from lots of parents every day asking, ‘Do you know, do you know? When’s it going to be approved?’” She added, “Think about how fast a new variant can spread.”

Still, the uptake of the vaccine in children — including in those ages 5-11, who began receiving Pfizer-BioNTech shots in early November — has been strikingly low. Only about one-third of the 28 million children in that age group have received at least one dose so far, according to CDC data. Three in 10 parents of children younger than 5 now say that they intend to get them vaccinated as soon as shots become available, according to a recent survey from the Kaiser Family Foundation.

Malia Jones, a scientist at the University of Wisconsin-Madison who studies vaccine hesitancy in children, predicted that parents would be even less likely to get shots for the youngest children. Parents of children in this age group, she said, have long been prone to believe misinformation about childhood vaccines, including theories that they are filled with toxins or cause autism.

“My expectation is that uptake is going to be really, really poor,” she said of the coronavirus shot for children younger than 5. “We’re already facing a very steep uphill battle for this age group, whether or not the efficacy data are there.”

© 2022 The New York Times Company



  
  সর্বশেষ
16 new Covid cases reported in country
Japan to provide 2,294 m Japanese Yen to Bangladesh; deals signed
China wants to import jute goods from Bangladesh
Donald Lu lauds Bangladeshi Americans for building foundation of ties between two countries

Chief Advisor: Md. Tajul Islam,
Editor & Publisher Fatima Islam Tania and Printed from Bismillah Printing Press,
219, Fakirapul, Dhaka-1000.
Editorial Office: 167 Eden Complex, Motijheel, Dhaka-1000.
Phone: 02-224401310, Mobile: 01720090514, E-mail: muslimtimes19@gmail.com